CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth

Poses Threat To Other JAK Inhibitors

 
• By Ayisha Sharma

New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.    

Person using key to unlock wooden figure
CTI Could Unlock A Bigger Chunk Of The Myelofibrosis Market • Source: Shutterstock

CTI BioPharma Corp.’s recently launched Vonjo can increase hemoglobin levels and reduce transfusion dependence in anemic myelofibrosis patients according to new data from the firm, which could support its expanded use.

Vonjo (pacritinib) first won a US accelerated approval for the treatment of myelofibrosis with severe thrombocytopenia early this year based...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D